Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

10 mg/day by mouth on days 1-21 of every 28 day cycle.

200 mcg subcutaneously every 2 weeks of a 28 cycle.